Liposome delivery systems for the treatment of Alzheimer's disease.

摘要: Alzheimer's disease (AD) will affect around 115 million people worldwide by the year 2050. It is associated with accumulation of misfolded and aggregated proteins (β-amyloid tau) in senile plaques neurofibrillary tangles found brain. Currently available drugs for AD only temporarily alleviate symptoms do not slow inevitable progression this disease. New are required that act on key pathologies order to arrest or reverse cognitive decline. However, there has been a spectacular failure rate clinical trials conventional small molecule biological agents. Targeted nanoliposomes represent viable promising drug delivery system have yet reached trials. They biocompatible, highly flexible, potential carry many different types therapeutic molecules across blood-brain barrier (BBB) into brain cells. can be tailored extend blood circulation time directed against individual multiple pathological targets. Modifications so far included use brain-penetrating peptides, together Aβ-targeting ligands, such as phosphatidic acid, curcumin, retro-inverted peptide inhibits Aβ aggregation. Combining several modifications multifunctional liposomes currently research area great interest. This review focuses recent liposomal approaches therapy, including mechanisms involved facilitating their passage BBB, evaluation new agents blocking and/or tau